{"product_id":"biolegend-640914","title":"Biolegend, 640914, FITC Annexin V Apoptosis Detection Kit with PI, 100tests","description":"\u003cp\u003eBioLegend's FITC Annexin V Apoptosis Detection Kit with PI has been specifically designed for the identification of apoptotic and necrotic cells.  Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer is recommended for use with Annexin V staining. Annexin V binding alone cannot differentiate between apoptotic and necrotic cells. To help distinguish between the necrotic and apoptotic cells we recommend use of our Propidium Iodide Solution (PI). Early apoptotic cells will exclude PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.  Propidium iodide is a fluorescent dye that binds to DNA. When excited by 488 nm laser light, it can be detected with in the PE\/Texas Red® channel with a bandpass filter 610\/10. It is commonly used in evaluation of cell viability or DNA content in cell cycle analysis by flow cytometry. \u003cbr\u003e\n100tests\u003cbr\u003e\nVerified Reactivity: Human, Mouse, Rat\u003cbr\u003e\nReported Reactivity: Other Species\u003cbr\u003e\nConcentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: Store between 2°C and 8°C. Do not freeze.Caution: Propidium Iodide Solution is toxigenic and mutagenic; handle with care.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)\u003cbr\u003e\nApplication Notes: Annexin V Staining Wash cells twice with cold BioLegend Cell Staining Buffer (Cat. No. 420201) and then resuspend the desired amount of cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 0.25-1.0 x 107 cells\/mL Transfer 100 µL of cell suspension in 5 mL test tube. Add 5 µL of fluorochrome conjugated Annexin V. Stain with a viability dye, such as PI (Cat. No. 421301), 7-AAD (Cat. Nos. 420403 \u0026amp; 420404), or Helix NP dyes (Cat. Nos. 425301, 425303, \u0026amp; 425305), if desired. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark. Add 400* µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. *For more concentrated samples, add a minimum of 200 µl of Annexin V Binding Buffer in this step. Analyze by flow cytometry. For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Ranhanathan P, et al. 2013. J AM Soc Nephrol. PubMed Yu J, et al. 2014. PloS One. 9:114650. PubMed Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed\u003cbr\u003e\nProduct Citations: Ho J, et al. 2016. PLoS Biol. 14:e2000117. PubMed Markowicz-Piasecka M, et al. 2020. Apoptosis. 25:426. PubMed Lyu X, et al. 2019. Oncol Rep. 41:3137. PubMed Lanna A, et al. 2022. Nat Cell Biol. 24:1461. PubMed Parisay I, et al. 2022. Dent Res J (Isfahan). 19:79. PubMed Oh C, et al. 2022. Cell Rep. 41:111688. PubMed Kamalabadi-Farahani M, et al. 2023. Cancer Rep (Hoboken). 6:e1693. PubMed Tintelnot J, et al. 2023. Nature. 615:168. PubMed Du Y, et al. 2023. iScience. 26:106114. PubMed Chen S, et al. 2023. Exp Ther Med. 25:159. PubMed Tan Z, et al. 2023. Mol Cell Probes. 69:101913. PubMed Ceniti C, et al. 2023. Foods. 12:. PubMed Vokshi BH, et al. 2023. Nat Commun. 14:3034. PubMed Wang L, et al. 2023. Nat Commun. 14:3366. PubMed Rodina A, et al. 2023. Nat Commun. 14:3742. PubMed Su T, et al. 2021. Metabolites. 11:. PubMed Tiu GC, et al. 2021. Dev Cell. 56:2089. PubMed Li H, et al. 2022. Transfusion. 62:663. PubMed Rashed FB, et al. 2022. Redox Biol. 52:102300. PubMed Yang K, et al. 2022. Sci Immunol. 7:eabn2888. PubMed Zaarour RF, et al. 2022. Int J Mol Sci. 23: . PubMed Khan AN, et al. 2022. Molecules. 27: . PubMed Wei W, et al. 2022. Mol Med Rep. 26: . PubMed Li D, et al. 2022. Nucleic Acids Res. 50:12462. PubMed Park J, et al. 2022. Animals (Basel). 12: . PubMed Zhang H, et al. 2022. Exp Ther Med. 24:763. PubMed Bachmann LM, et al. 2023. Molecules. 28: . PubMed Song X, et al. 2022. Cancer Discov. 12:1294. PubMed Caballero M, et al. 2022. Front Mol Biosci. 9:752668. PubMed Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed Li MM, et al. 2018. Int J Infect Dis. 70:72. PubMed Fang H, et al. 2022. Exp Ther Med. 24:440. PubMed Chen J, et al. 2021. Antioxidants (Basel). 10:. PubMed Shimonosono M, et al. 2021. Biomolecules. 11:. PubMed Wang C, et al. 2021. Clin Transl Med. 11:e522. PubMed Yuan L, et al. 2015. Endocr Relat Cancer. 22: 577 - 591. PubMed Belo H, et al. 2015. PLoS One. 10: e0139740. PubMed Morita K, et al. 2020. Cell. 702:181. PubMed Yang J, et al. 2021. Oncoimmunology. 1875638:10. PubMed Guo Q, et al. 2018. Front Immunol. 9:1197. PubMed Soonthornchai W, et al. 2019. Asian Pac J Allergy Immunol. N\/A. PubMed Son Y, et al. 2020. Mol Metab. 39:101005. PubMed Xie T, et al. 2021. Ann Transl Med. 9:1249. PubMed Kocak P, et al. 2021. Macromol Biosci. 21:e2000287. PubMed Li D, et al. 2022. Sci Adv. 8:eabm0478. PubMed Choromanska A, et al. 2020. Biomed Rep. 13:32. PubMed Mahmoud A, et al. 2016. Int J Toxicol. 35: 429 - 437. PubMed Liu J, et al. 2015. Biochem Biophys Res Commun. 463: Pags 262-267. PubMed Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed Neumann CKA, et al. 2020. Mol Metab. 34:136. PubMed Ali DM, et al. 2019. Cell Death Discov. 5:128. PubMed Yao J, et al. 2018. Onco Targets Ther. 11:3793. PubMed Chang T, et al. 2016. Sci Rep. 6:23403. PubMed Shao M, et al. 2018. Evid Based Complement Alternat Med. 2018:6049498. PubMed Coelho CC, et al. 2019. Sci Rep. 9:11050. PubMed Orgaz JL, et al. 2020. Cancer Cell. 37:85. PubMed Vashist A, et al. 2022. Asian Pac J Cancer Prev. 23:3629. PubMed Korencak M, et al. 2019. JCI Insight. 4. PubMed Zhang W, et al. 2021. J Clin Invest. 131:. PubMed Kang DY, et al. 2022. J Oncol. 2022:6737248. PubMed Saboor-Maleki S, et al. 2016. Technol Cancer Res Treat. 10.1177\/1533034616650119. PubMed Tatsuno K, et al. 2019. Cell Death Dis. 10:578. PubMed Ouyang J, et al. 2019. J Surg Res. 233:221. PubMed Xiao Y, et al. 2020. Nucleic Acids Res. 48:11113. PubMed Shen L, et al. 2021. Cell Death Discov. 7:392. PubMed Lian W, et al. 2022. J Immunol Res. 2022:3129765. PubMed Wu J, et al. 2020. Immunity. 53:115. PubMed Sareddy G, et al. 2016. Sci Rep. 6: 24185. PubMed Xie L, et al. 2020. Front Oncol. 1.354166667. PubMed Fei X, et al. 2019. Cancer Manag Res. 11:4781. PubMed Balachandran C, et al. 2017. Biomed Pharmacother. 10.1016\/j.biopha.2017.06.096. PubMed Kiss E, et al. 2021. Int J Mol Sci. 22:. PubMed Cao W, et al. 2016. Nat Commun. 7:11687. PubMed Finetti F, et al. 2020. Cell Death Differ. 27:310. PubMed Xing W, et al. 2020. J Recept Signal Transduct Res. 1:. PubMed Virumbrales–Muñ oz M, et al. 2019. Sci Rep. 9:6199. PubMed Allur Subramaniyan S, et al. 2018. Cell Commun Adhes. 24:19. PubMed Chen J, et al. 2021. J Oncol. 2021:5572402. PubMed Liu R, et al. 2021. Oncol Lett. 21:06. PubMed Perez E, et al. 2020. J Immunol. 205:2489. PubMed Callender LA, et al. 2021. Nat Commun. 12:3379. PubMed Blue E, et al. 2015. Diabetes. 64: 2664 - 2675. PubMed Kongkavitoon P, et al. 2016. PLoS One. 11: 0146696. PubMed Coden ME, et al. 2020. J Immunol. 204:438. PubMed Sohrabi Y, et al. 2019. Front Immunol. 9:3155. PubMed Changizi V, et al. 2021. Iran J Med Sci. 46:291. PubMed Zhang N, et al. 2021. Atherosclerosis. 334:39. PubMed Hu K, et al. 2020. Nat Commun. 2778:11. PubMed Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed Shin JJ, et al. 2020. Cell Rep. 32:108093. PubMed Soonthornchai W, et al. 2021. Sci Rep. 11:14186. PubMed Still C 2nd, et al. 2021. Cell Reports Medicine. 2(7):100343. PubMed Tailor D, et al. 2020. Br J Cancer. . PubMed Ryva B, et al. 2019. Front Oncol. 9:100. PubMed Flegkas A, et al. 2019. Medicines (Basel). 6:1. PubMed Wu A, et al. 2020. Cell Death Dis. 11:40. PubMed Patil M, et al. 2021. Circ Res. 129:1006. PubMed Abokyi S, et al. 2021. Int J Mol Sci. 22:. PubMed Huang S, et al. 2022. J Cancer. 13:2662. PubMed Merikhian P, et al. 2022. Mol Oncol. 16:485. PubMed Zhou Y, et al. 2021. NPJ Regen Med. 6:34. PubMed Ma H, et al. 2015. Sci Rep. 5: 15121. PubMed Kan L, et al. 2015. PLoS One. 10: 0144513. PubMed Wang YL, et al. 2021. Environ Health Perspect. 129:57003. PubMed Zhou L, et al. 2021. Front Oncol. 11:668617. PubMed Dudek M, et al. 2021. Nature. 592:444. PubMed Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed Zhou Q, et al. 2020. J Invest Dermatol. . PubMed Chou ST, et al. 2020. Chin Med. 0.678472222. PubMed Weiss R, et al. 2015. Innate Immunity. 21: 813 - 826. PubMed Yu J, et al. 2014. PLoS One. 9:114650. PubMed Viereckl MJ, et al. 2022. Biomolecules. 12:. PubMed Roupakia E, et al. 2021. Cancers (Basel). 13:. PubMed Pires D, et al. 2021. Front Immunol. 12:647728. PubMed Lonardi S, et al. 2020. Cancer Immunol Res. 829:8. PubMed Cho S, et al. 2019. Transl Oncol. 0.820138889. PubMed Wang JS, et al. 2021. Nat Commun. 12:6271. PubMed Li XR, et al. 2020. Neoplasma. 67:982. PubMed Zakharova I, et al. 2022. Front Bioeng Biotechnol. 10:772981. PubMed Yang Y, et al. 2022. Int J Mol Sci. 23:. PubMed Choromanska A, et al. 2020. Pharmaceutics. 12:00. PubMed Levy G, et al. 2015. PLoS One. 10: 0136070. PubMed Zamani K, et al. 2021. BMC Biotechnol. 21:68. PubMed Biadglegne F, et al. 2021. Mol Med Rep. 24:. PubMed Li C, et al. 2018. Cell Physiol Biochem. 45:366. PubMed Wang X, et al. 2020. Onco Targets Ther. 13:1691. PubMed Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed Zhong X, et al. 2021. Oncol Lett. 245:21. PubMed Wang W, et al. 2020. Cancer Cell Int. 1.06875. PubMed Lin B, et al. 2020. Mol Med Rep. 21:2171. PubMed Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed Lauko A, et al. 2022. Cell Rep. 40:111348. PubMed\u003cbr\u003e\nBiology Area: Apoptosis\/Tumor Suppressors\/Cell Death, Cell Biology, Neuroscience\u003cbr\u003e\nGene ID: 308\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Annexin A5 Apoptosis Detection Kit, Dead, Apoptosis\u003cbr\u003e\nQ: How is your Annexin made and what sequence does it cover?\u003cbr\u003e\nA: It is made in E. coli, covering human aa Met1-Asp320.\u003cbr\u003e\nQ: How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?\u003cbr\u003e\nA: Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.\u003cbr\u003e\nQ: Why do I need to use Annexin V Binding Buffer?\u003cbr\u003e\nA: Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.\u003cbr\u003e\nQ: Can I use RPMI during Annexin V staining?\u003cbr\u003e\nA: It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.\u003cbr\u003e\nQ: Can I freeze Annexin V conjugates?\u003cbr\u003e\nA: It should not be frozen as it will lead to loss of biological activity due to dimerization.\u003cbr\u003e\nQ: Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?\u003cbr\u003e\nA: Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46864300671145,"sku":"640914","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-640914","provider":"Iright","version":"1.0","type":"link"}